From the stock head article. The share price for Botanix is madness as we all know:
In addition, companies undertaking an FDA review on their first drug have typically re-rated through the FDA review, seeing an average 102% re-rate and $760 million valuation by this time into the review.“Whereas BOT has only re-rated 58%, and from a small base, with its $140 million valuation well below the peer average.“So our analysis suggests BOT may be the cheapest ASX-listed company to have filled for an FDA New Drug application,” said Euroz.“We maintain our Speculative Buy recommendation with an increased 28c per share.”
BOT - Anything but charting, page-4566
-
- There are more pages in this discussion • 4,706 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
-0.015(3.95%) |
Mkt cap ! $660.6M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 37.5¢ | 35.0¢ | $2.027M | 5.581M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 423793 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 154813 | 5 |
View Market Depth
| Last trade - 10.56am 15/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |